Elevated levels of asymmetric dimethylarginine are associated with lower CD4+ count and higher viral load in HIV-infected individuals

Atherosclerosis

Volumn 229, Issue 1, 2013, Pages 246-252

  Parikh, Rushi V ^a   Scherzer, Rebecca ^a   Grunfeld, Carl ^a   Nitta, Elaine M ^b   Leone, Anna ^c   Martin, Jeffrey N ^a,b   Deeks, Steven G ^b   Ganz, Peter ^b   Hsue, Priscilla Y ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Oxonon BioAnalysis   (United States)

Author keywords

Asymmetric dimethylarginine; Endothelial dysfunction; HIV; Nitric oxide

Indexed keywords

ANTIRETROVIRUS AGENT; HIGH DENSITY LIPOPROTEIN; N(G),N(G) DIMETHYLARGININE;

ADULT; AMINO ACID BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS LOAD;

ADULT; ARGININE; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NITRIC OXIDE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; VIRAL LOAD;

EID: 84879420309     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.04.025     Document Type: Article

References (33)

1. Triant V.A., et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with HIV disease. JClin Endocrinol Metab 2007.
2. Hsue P.Y., et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004, 109(13):1603-1608.
3. Deeks S.G. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011, 62(1):141-155.
4. Ganz P., Vita J.A. Testing endothelial vasomotor function. Circulation 2003, 108(17):2049-2053.
5. Cooke J.P. Asymmetrical dimethylarginine. Circulation 2004, 109(15):1813-1818.
6. Cooke J.P., Ghebremariam Y.T. DDAH says NO to ADMA. Arteriosclerosis Thromb Vasc Biol 2011, 31(7):1462-1464.
7. Abbasi F., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001, 88(10):1201-1203.
8. Schwedhelm E., et al. Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: results from the Framingham offspring cohort. Clin Chem 2009, 55(8):1539-1545.
9. Zhang W.Z., et al. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress. Hypertension 2006, 48(2):278-285.
10. Boger R.H., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998, 98(18):1842-1847.
11. Stuhlinger M.C., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002, 287(11):1420-1426.
12. Fujiwara N., et al. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 2000, 101(8):856-861.
13. Lu T.M., et al. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol 2011, 153(2):135-140.
14. Boger R.H., et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009, 119(12):1592-1600.
15. Schnabel R., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005, 97(5):e53-e59.
16. Kurz K., et al. Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers. Pharmacol Res 2009, 60(6):508-514.
17. Jang J.J., et al. Asymmetric dimethylarginine and coronary artery calcium scores are increased in patients infected with human immunodeficiency virus. Atherosclerosis 2011, 217(2):514-517.
18. Leone A., et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. The Lancet 1992, 339(8793):572-575.
19. Hsue P.Y., et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. Aids 2006, 20(18):2275-2283.
20. Teerlink T., et al. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002, 303(2):131-137.
21. Willemsen N., et al. Protein methylation is required to maintain optimal HIV-1 infectivity. Retrovirology 2006, 3(1):92.
22. Baker J.V., et al. HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. JAcquir Immune Defic Syndr 2012.
23. Neuhaus J., et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. JInfect Dis 2010, 201(12):1788-1795.
24. Hunt P.W., et al. Tcell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. JInfect Dis 2003, 187(10):1534-1543.
25. Hsue P.Y., et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. Aids 2009, 23(9):1059-1067.
26. Hsue P.Y., et al. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. JAm Heart Assoc 2012, 1:e000422. 10.1161/JAHA.111.000422.
27. Hsue P.Y., et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. Aids 2009, 23(15):2021-2027.
28. Torriani F.J., et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. JAm Coll Cardiol 2008, 52(7):569-576.
29. Solages A., et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006, 42(9):1325-1332.
30. Lichtenstein K.A., et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010, 51(4):435-447.
31. Triant V.A., et al. Association of immunologic and virologic factors with myocardial infarction rates in a US Healthcare system. JAcquir Immune Defic Syndr 2010.
32. Juonala M., et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in Young Finns study. Circulation 2007, 116(12):1367-1373.
33. Fard A., et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arteriosclerosis Thromb Vasc Biol 2000, 20(9):2039-2044.